Impact of Circular 10 on the use of domestically produced western medicines that are covered by the HI fund in hospitals The basis for promulgating Circular 10 In order to guide Article 50 of Law on Bidding No. 43/2013/QH13 of November 26th, 2013 (For domestically produced drugs which were announced by the Ministry of Health and meet the requirements of treatment, drug price and supply capacity, the bidding documents are required to stipulate that the contractor is not allowed to offer imported drugs), on May 5th, 2016, the Ministry of Health issued a list of domestically produced drugs that meet the requirements of treatment, drug price, and supply capacity.